Labiotech.eu

car t cd19 fda juno therapeutics cerebral edema

News and Trends 18 Jul 2016

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA after 3 deaths, which could be treatment-related. How will this impact the field, given that most CAR-T Biotechs share the same target? UPDATE (article originally published on 8/7/2016): the FDA has allowed Juno Therapeutics to resume its CAR-T trial with […]

July 18, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 18 Jul 2016

Switzerland discovers Pomegranate ‘Anti-Ageing’ Effect and founds Biotech

Researchers at the École Polytechnique Fédérale de Lausanne (EPFL) have uncovered a molecule in the pomegranate fruit which can prolong the lifespan of animal models. The co-authors who published in Nature went to co-found a biotech Amazentis to develop the wonder molecule into clinical trials. There are many underlying factors to what happens to our bodies as we age. However, […]

July 18, 2016 - 3 minutesmins - By Dani Bancroft

geg tech native advertising biotech digitaL MARKETING

News and Trends 18 Jul 2016

How did we increase the online traffic of this Biotech by 289%?

Helping Biotech companies become more visible is what we do every day — here’s a case study of how we successfully helped GEG-Tech. GEG-Tech is specialized in customized design and production of lentiviral vectors. Thanks to our solution, we helped brought more visitors to their website. The campaign was a great success, leading this company increase its sales and close a deal with a […]

July 18, 2016 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2016

UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious disease and cancer. It has therefore just acquired a Swiss antibody manufacturing biotech Delenex, to help its progress into the CAR-T field. Update 20/07/16: Cell Medica has also just received EMA Orphan Drug Designation for their CMD-003 candidate. This means it can obtain regulatory and […]

July 15, 2016 - 3 minutesmins - By Dani Bancroft

biotech infographic personalised edicine genetic disease

News and Trends 15 Jul 2016

Infographic: What are the key challenges in Personalized Medicine?

Personalized medicine is the way forward in tackling hard-to-treat indications. Here are some of the challenges in R&D of such therapies in biotech. By exploring use of autologous therapies, the chance of adverse responses from immunogenicity is reduced, making the treatment more targeted and effective (as doses can be higher). However, there are challenges in […]

July 15, 2016 - 1 minutemin - By Dani Bancroft

genomics proteomics merger syngis expedeon biotech

News and Trends 15 Jul 2016

These Two ‘Omics’ Companies are Merging to Create a New Player in Life Sciences

Sygnis is planning to acquire Expedeon, to join its portfolio in NGS reagents with Expedeon’s presence in the proteomics market – and become a leading player in life science reagents. UPDATE (article originally published on June 6th, 2016): Sygnis successfully completes Rights Offering and Private Placement and secured the acquisition of Expedeon Holdings Ltd. on July 15th, 2016. See […]

July 15, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 15 Jul 2016

Compugen is Hunting down ‘Hot’ zone Targets for Immuno-Oncology

Israel, we’re on our way! We leave Denmark with a smile and head down to sunny Tel-Aviv, where Compugen, a big Israeli-based leading drug discovery company and our Biotech of The Week, is located. City: Tel-Aviv (Israel) Founded: 1993 Employees: 93 (as of 03/2016) Financial Data: €257.2M Market Cap (on 22/03/2016) CEO: Anat Cohen-Dayan Mission: Compugen-discovered drug targets are primarily […]

July 15, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 Jul 2016

Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

Themis is a Vienna-based vaccine developer. Together with the Institut Pasteur, it is now planning to use a measles vaccine construct to develop and start Zika vaccine trials within the next 12 months. Themis has successfully extended its existing license agreement with Institut Pasteur in Paris, which grants the company a broad access to a well-established virus vaccine vector technology. The […]

July 14, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Jul 2016

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Getting up from a wheelchair is a shared dream of paralyzed people all across the world. A dream that might soon become true thanks to a new skin-like implant that directly stimulates the patients’ spinal cord through electric pulses. The sci-fi technology developed by researchers at École Polytechnique Fédérale of Lausanne (EPFL) in Switzerland has […]

July 14, 2016 - 2 minutesmins - By Lourdes Riquelme

oxitec brazil mosquito gmo vector control zika dengue malaria city

News and Trends 14 Jul 2016

UPDATE: Brazilian city to be first in World to deploy GM Mosquitos against Dengue Fever

Oxitec‘s genetically engineered Mosquito trial is being expanded in Brazil’s Piracicaba region, to cover a city of over 60,000 people. With support from Ministry officials and the WHO, this UK biotech is making serious progress with their transgenic organism solution for Infectious diseases. UPDATE: (Article originally published 3/06/16). Just announced (14/07/16): The results from the trial […]

July 14, 2016 - 4 minutesmins - By Dani Bancroft

pharnext marie tooth disease IPO pharnext

News and Trends 14 Jul 2016

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s. Based in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. New partners to join this biotech in the €31M IPO include Galapagos […]

July 14, 2016 - 2 minutesmins - By Dani Bancroft

servier sorrento pd 1 biotech chemo car t cancer

News and Trends 13 Jul 2016

French Pharma licenses California PD-1 Cancer Antibody for €710M

San Diego’s Sorrento Therapeutics has bagged a quarter-billion euro deal with Servier. The French Pharma giant will develop Sorrento’s PD-1 targeting platform – a key checkpoint inhibitor in Immuno-Oncology. Sorrento’s proprietary G-MAB library platform was used to identify and generate STI-A1110, an antibody which targets PD-1, one of the key targets in the rapidly developing immuno-oncology therapy […]

July 13, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

Switzerland discovers Pomegranate ‘Anti-Ageing’ Effect and founds Biotech

How did we increase the online traffic of this Biotech by 289%?

UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

Infographic: What are the key challenges in Personalized Medicine?

These Two ‘Omics’ Companies are Merging to Create a New Player in Life Sciences

Compugen is Hunting down ‘Hot’ zone Targets for Immuno-Oncology

Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

UPDATE: Brazilian city to be first in World to deploy GM Mosquitos against Dengue Fever

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

French Pharma licenses California PD-1 Cancer Antibody for €710M

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!